<DOC>
	<DOCNO>NCT00515983</DOCNO>
	<brief_summary>Background : Sixteen melanoma patient ( 1 stage IIC , 8 stage III , 7 stage IV ) treat Phase I study evaluate safety immune response , vaccine ( DC/Apo-Nec ) compose autologous dendritic cell ( DCs ) load mixture apoptotic/necrotic melanoma cell line ( Apo-Nec ) . Methods : PBMC obtain leukapheresis DCs generate monocyte culture presence GM-CSF IL-4 serum-free medium . Immature DCs ( iDCs ) load gamma-irradiated Apo-Nec cell inject id without adjuvant . Cohorts four patient give four vaccine 5 , 10 , 15 , 20 x106 DC/Apo-Nec per vaccine , two week apart . Results : The vaccine well tolerated patient . Toxicity vaccine mild , toxicity-limiting dose reach . We find 42.3 ±13.7 % melanoma patients´ iDCs able phagocyte Apo-Nec cell wich induced DCs maturation , evidence increase expression CD83 , CD80 , CD86 , HLA class I II compare iDCs . Also , phagocytosis , 75.2 ±16 % reduction Dextran-FITC endocytosis observe compare iDCs . CCR7 upregulated upon Apo-Nec phagocytosis DCs patient accordingly vitro DC/Apo-Nec cell able migrate towards MIP-3 beta . The DTH score increase significatively patient first vaccination slightly decrease fourth vaccine ( Mann-Whitney Test , p &lt; 0.05 ) . For patient # 1 positive DTH reaction detect tumor irradiated cell . The presence CD8+ T lymphocytes specific gp100 Melan A/MART-1 Ags study tetramers bind HLA-A*0201 patient ( 7 /15 patient ) vaccination . Two patient remain NED increase Ags specific T lymphocytes vaccination . No humoral response Apo-Nec cell detect . With mean follow-up 44.5 month post-surgery , stage IIC pt NED , 7/8 stage III pt NED 7/7 stage IV patient progress . Conclussions : We conclude DC/Apo-Nec vaccine well tolerate , induces specific immunity melanoma Ags stage III patient may prolong disease-free survival , afford protection relapse adjuvant setting .</brief_summary>
	<brief_title>Vaccination Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>histologically confirm cutaneous melanoma stage IIB , IIC , III IV ( AJCC ) pts minimal nondetectable disease ( NED ) surgery assert CAT scan . Melanoma pts unknown primary tumor site could include study life expectancy &gt; 6 month age : 15 60 year performance status ( ECOG ) 0 1 pt stage III disease previously treat IFNalpha , either finish treatment suspend due disease progression , toxicity clinical reason . Alternatively , pt start IFNalpha within six month surgery could include study suitable venous access leukapheresis procedure laboratory eligibility criterion include : hemoglobin &gt; 10 gr % ; WBC count &gt; 4800/mm3 , platelet &gt; 150.000/mm3 , total direct bilirubin , serum oxalacetic transaminase glutamic pyruvic transaminase &lt; 1.5 fold upper normal value ; LDH &lt; 450 mU/ml absence pregnancy , serum βHCG determine one week vaccination premenopausal woman serum creatinine &lt; 1.4 mg % chemotherapy , radiotherapy biological treatment previous month concurrent medication corticosteroid NSAIDs l active brain metastasis normal ECG pt give write informed consent inclusion Study . Ocular melanoma melanoma mucosa Active brain metastases Other previous carcinoma ( exeption cervical situ basal cell carcinoma adequately treat ) Pregnant breastfeed woman Cardiac Arythmia , severe heart disease . Bacterial , mycotic viral serious infection ( &gt; grade 2 accord NCI common toxicity criterion ) HIV , B C Hepatitis previous infection Primary secondary immunodeficiency Other disease require treatment regular corticoid non steroid antiinflammatory drug COX2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>melanoma</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>apoptotic/necrotic cell</keyword>
	<keyword>therapeutic vaccine</keyword>
</DOC>